Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy
C PitartJ Vila

Abstract

Ceftazidime-avibactam and comparator antibiotics were tested by the broth microdilution method against 200 Enterobacteriaceae and 25 Pseudomonas aeruginosa strains resistant to fluoroquinolones (including strains with the extended-spectrum β-lactamase [ESBL] phenotype and ceftazidime-resistant strains) collected from our institution. The MICs and mechanisms of resistance to fluoroquinolone were also studied. Ninety-nine percent of fluoroquinolone-resistant Enterobacteriaceae strains were inhibited at a ceftazidime-avibactam MIC of ≤4 mg/liter (using the susceptible CLSI breakpoint for ceftazidime alone as a reference). Ceftazidime-avibactam was very active against ESBL Escherichia coli (MIC90 of 0.25 mg/liter), ESBL Klebsiella pneumoniae (MIC90 of 0.5 mg/liter), ceftazidime-resistant AmpC-producing species (MIC90 of 1 mg/liter), non-ESBL E. coli (MIC90 of ≤0.125 mg/liter), non-ESBL K. pneumoniae (MIC90 of 0.25 mg/liter), and ceftazidime-nonresistant AmpC-producing species (MIC90 of ≤0.5 mg/liter). Ninety-six percent of fluoroquinolone-resistant P. aeruginosa strains were inhibited at a ceftazidime-avibactam MIC of ≤8 mg/liter (using the susceptible CLSI breakpoint for ceftazidime alone as a reference), with a MIC90 of 8 mg/lite...Continue Reading

References

May 1, 1995·Antimicrobial Agents and Chemotherapy·J VilaT Jimenez de Anta
Feb 1, 1996·Antimicrobial Agents and Chemotherapy·J VilaM T De Anta
Dec 11, 1999·The Journal of Antimicrobial Chemotherapy·M M NaviaJ Vila
Feb 27, 2001·The Journal of Antimicrobial Chemotherapy·D M Livermore
Jun 19, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patricia A BradfordJohn Quale
Aug 31, 2010·The Journal of Antimicrobial Chemotherapy·Shazad MushtaqDavid M Livermore
Nov 3, 2010·Antimicrobial Agents and Chemotherapy·David M LivermoreNeil Woodford
Aug 24, 2013·The Lancet Infectious Diseases·L Silvia Munoz-PriceJohn P Quinn
Aug 17, 2014·Diagnostic Microbiology and Infectious Disease·Robert K FlammRonald N Jones

❮ Previous
Next ❯

Citations

Oct 18, 2016·MedChemComm·Jed F Fisher, Shahriar Mobashery
Apr 5, 2016·Expert Review of Anti-infective Therapy·Bradley J Gardiner, Yoav Golan
Jun 15, 2017·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Adnan AlatoomImran Mirza
Nov 8, 2017·Infection·Felipe Francisco TuonMarcelo R Formigoni-Pinto
Aug 8, 2018·Antimicrobial Agents and Chemotherapy·Fernando Sanz-GarcíaJosé Luis Martínez

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.